Axitinib + Ipilimumab in Advanced Melanoma
The goal of this clinical research study is to find out if taking axitinib with ipilimumab is effective in treating advanced melanoma.
Melanoma
DRUG: Ipilimumab|DRUG: Axitinib
Overall Response Rate, Overall Response Rate (ORR) defined as proportion of patients to have achieved a complete or partial response per irRECIST and RECIST v1.1 criteria., Up to 24 months
Progression Free Survival, Progression Free Survival (PFS) is defined as the length of time from start of study treatment to the earlier of the first documentation of disease progression or death from any cause., Up to 5 years|Overall Survival, Overall Survival (OS) is defined as the length of time from start of treatment to date of death from any cause., Up to 5 years|Duration of Response, Duration of Response is defined as the interval from the first documentation of Complete Response (CR) or Partial Response (PR) to documentation of progressive disease or death from any cause., Up to 5 years|Clinical Benefit Rate, Clinical Benefit Rate is defined as the proportion of patients who achieve a Complete Response (CR), Partial Response (PR) or durable Stable Disease (SD) of at least 6 months from start of study treatment., Up to 12 months
The safety and tolerability of the combination of ipilimumab and axitinib will be tested in advanced melanoma patients who are intolerable/refractory to anti-PD-1/PD-L1 therapy and have not previously received treatment with ipilimumab.